Samsung Biologics要约收购PolyPeptide 97.66%股份,交易待监管批准
Samsung Biologics Secures 97.66% of PolyPeptide Shares in Tender Offer
Samsung Biologics于2026年11月2日宣布,其通过瑞士子公司Samsung Peptide AG发出的公开要约收购已获PolyPeptide Group 97.66%的已发行股本及投票权有效接受,要约价为每股44.31瑞士法郎现金,交易价值约14.6亿瑞士法郎。
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
Samsung Biologics announced on November 2, 2026, that 97.66% of PolyPeptide Group's issued share capital and voting rights had been validly tendered into its public tender offer by the end of the additional acceptance period on October 30, 2026.¹ The offer, made through Swiss subsidiary Samsung Peptide AG, would bring a specialized peptide API contract development and manufacturing organization (CDMO) under a biologics-focused CDMO. Samsung Biologics expects the transaction to close toward the end of 2026 or in the first quarter of 2027, subject to regulatory approvals.¹
Key facts
- Acquirer: Samsung Biologics (via Samsung Peptide AG)
- Target: PolyPeptide Group (peptide API CDMO)
- Offer price: CHF 44.31 (US$54.15) per share in cash
- Deal value: about CHF 1.46 billion (US$1.78 billion)
- Shares tendered: 97.66% (provisional)
- Expected completion: end of 2026 or first quarter 2027
- Next steps: squeeze-out and SIX Swiss Exchange delisting
- PolyPeptide footprint: 6 GMP facilities in Europe, the US, and India
- Strategic focus: modality expansion into peptides, including GLP-1
When Samsung Biologics first announced the offer in July 2026, John Rim, chairman of the board of directors and CEO, framed the deal around modality expansion. "This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1 [glucagon-like peptide-1], but by also boosting our geographic reach and proximity further within the United States, Europe, and India," Rim said in a company press release at the time.²
What are the terms and next steps?
Samsung Biologics offered CHF 44.31 (US$54.15) in cash per share, for an implied equity value of approximately CHF 1.46 billion (US$1.78 billion).² Based on preliminary figures, 32,350,302 PolyPeptide shares were tendered.¹ The definitive notice of the end result is expected on November 5, 2026.¹ Settlement, originally indicated for November 13, 2026, has been postponed pending regulatory approvals in several countries.¹ After settlement, Samsung Peptide intends to pursue a squeeze-out of remaining minority shareholders and delist PolyPeptide from the SIX Swiss Exchange.¹
What does the deal mean for biomanufacturing?
Samsung Biologics has 785,000 L of biomanufacturing capacity across its Bio Campus I and II sites in Korea and 60,000 L at its facility in Rockville, Maryland, for a total global capacity of 845,000 L.¹ That capacity supports modalities including multispecific antibodies, fusion proteins, antibody-drug conjugates (ADCs), and messenger RNA therapeutics.¹ PolyPeptide focuses on peptide-based APIs and operates 6 GMP-certified facilities in Europe, the US, and India.¹ Samsung Biologics said the combination would create an "end-to-end multi-modality CDMO platform."²
The deal follows a broader shift toward complex modalities at the company. In an earlier BioPharm International® interview,3 Kasper Øland, vice president of sales execution for contract development organization services at Samsung Biologics, discussed the company's customer pipeline. More than 55% of that pipeline is complex molecules, including bispecific and multispecific antibodies and ADCs.3
The acquisition also stood out to industry observers. In a July 2026 Pharmaceutical Technology® interview,4 Saharsh Davuluri, vice chairman and managing director of Neuland Labs, said he was surprised by the deal. He had expected CDMOs to pursue more organic capacity expansion and new US investment.4
Why does it matter for the peptides market?
In its July 2026 announcement, Samsung Biologics described peptide therapeutics as "one of the fastest-growing segments of the biopharmaceutical industry."² It cited demand in obesity and diabetes, including GLP-1 therapies, as well as oncology and other emerging indications.² PolyPeptide reported significant exposure to metabolic diseases, including glucagon-like peptide-1 (GLP-1).¹ Davuluri in his interview similarly noted that peptide demand is expanding beyond metabolic uses into other therapeutic areas.4
The GLP-1 field has recently faced increased competition. China’s March 2026 approval of Sciwind Biosciences' ecnoglutide for chronic weight management, for example, intensified competition in a GLP-1 market led by Novo Nordisk and Eli Lilly.5
What are the limitations?
The transaction is not yet complete and remains subject to regulatory approvals, and the tender figures are preliminary. Samsung Biologics has not disclosed integration plans, capacity investments, or changes to PolyPeptide's operations.
References
- Samsung Biologics. Samsung Biologics publishes provisional end result for PolyPeptide tender offer with 97.99% participation rate. Press release. Published November 2, 2026. Accessed November 2, 2026. https://samsungbiologics.com/media/company-news/samsung-biologics-publishes-provisional-end-result-for-polypeptide-tender-offer-with-97dot99
- Samsung Biologics. Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India. Press release. Published July 20, 2026. Accessed November 2, 2026. https://samsungbiologics.com/media/company-news/samsung-biologics-announces-all-cash-offer-to-acquire-polypeptide
- Jacobus N, Øland K, Mirasol F. Samsung Biologics' Kasper Øland discusses why biopharma's shift to complex molecules is redefining what biotech companies require from CDMO partners. BioPharm International. Published July 1, 2026. Accessed November 2, 2026. https://www.biopharminternational.com/view/samsung-biologics-kasper-land-biopharma-complex-molecules-biotech-cdmo-partners
- Davuluri S. Saharsh Davuluri's midyear take on the shifting CDMO landscape covers out-licensing, agility, and investment surprises. PharmTech. Published July 22, 2026. Accessed November 2, 2026. https://www.pharmtech.com/view/saharsh-davuluri-s-midyear-take-on-the-shifting-cdmo-landscape-covers-out-licensing-agility-and-investment-surprises
- Sciwind Biosciences. Sciwind Biosciences announces ecnoglutide injection approved by China’s National Medical Products Administration (NMPA) for chronic weight management. Press Release. Published March 6, 2026. Accessed Nov. 2, 2026. https://www.sciwindbio.com/portal/index/newsdetail/id/125/category_id/5.html
Related to this article
October 30th, 2026
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
October 30th, 2026
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
November 2nd, 2026
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
October 30th, 2026
This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
October 30th, 2026
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
October 29th, 2026
DAX-044 aims to confine IL-12 activity to tumors and avoid the toxicity that has limited IL-12 therapy, with phase 1 testing expected in 2027.
October 29th, 2026
The proposed FDA guidance would let sponsors add patient-specific gene editing variants to approved BLAs via in vitro data, with comments due November 27, 2026.
October 28th, 2026
All 9 patients treated with BB-301 gene therapy met formal response criteria for improved swallowing in an ongoing OPMD trial.
来源:BioPharm International · biopharminternational.com







